Better to Treat Rheumatoid Arthritis in its Early Stages
EULAR 2017: Undifferentiated arthritis or very early rheumatoid arthritis should be treated soon after diagnosis to prevent advanced arthritis.
Romosozumab Continues to Build Bone, Reduce Fracture Risk
EULAR 2017: Romosozumab reduces the risk of clinical vertebral fractures in postmenopausal women with osteoporosis by as much as five times.
Sustained Remission in RA Occurs, but is Poorly Reported
In this review, researchers document the factors most commonly associated with sustained remission in rheumatoid arthritis patients receiving anti-TNF therapy.
Tocilizumab Linked to High LDL, but not Cardiovascular Risk in RA
Tocilizumab may be associated with increasing LDL cholesterol in rheumatoid arthritis, but a new study shows that it is not associated with increased cardiovascular risk.
Some Early Spondyloarthritis Features More Definitive than Others
Sacroiliitis on MRI and peripheral arthritis appear to be the best indicators of disease in this group, researchers report.
Choice of Second-Line Therapy in RA Influenced by MBDA Score
Rheumatoid arthritis patients with lower MBDA scores respond better to triple therapy vs. methotrexate and infliximab combo.
15 Recommendations for Treating Glucocorticoid-Induced Osteoporosis
For the first time in seven years, the ACR has new treatment recommendations for glucocorticoid-induced osteoporosis. In this slideshow, we highlight the new guidelines.
By clicking Accept, you agree to become a member of the UBM Medica Community.